Drugs / Kisunla
Kisunla cost
donanemab-azbt · Eli Lilly. Every official price for Kisunla, side by side, with who pays it.
Short answer
FDA approved Kisunla (donanemab-azbt) on Jul 2, 2024. Eli Lilly lists Kisunla at $731.49 per 350 mg/20 mL vial, as of October 1, 2026 (date of the list price on Lilly's pricing page). Medicare Part B pays up to $4.185 per 2 mg for Kisunla given by IV infusion (October 1, 2026 to December 31, 2026).412
Source: FDA, Eli Lilly and CMS · checked Oct 25, 2026
Kisunla: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per 350 mg/20 mL vial | $731.491 | Eli Lilly's price to wholesalers (WAC). Most people don't pay it directly. | October 1, 2026 (date of the list price on Lilly's pricing page) |
| Medicare Part B payment limit per 2 mg, Kisunla given by IV infusion | $4.1852 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Approved by the FDA on Jul 2, 2024 as a new drug (donanemab-azbt).4
- FDA-approved use on the approval date, in FDA's words: "To treat Alzheimer’s disease."4 The current label may list more uses; ask your doctor or pharmacist what applies to you.
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $731.491 | Per 350 mg/20 mL vial. The price the maker charges wholesalers; most people do not pay it directly. | October 1, 2026 (date of the list price on Lilly's pricing page) (checked Oct 25, 2026) |
| Medicare Part B payment limit Kisunla given by IV infusion (donanemab-azbt) · HCPCS J0175 | $4.1852 | Per 2 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) | Not listed | This drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies. | — |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3
Kisunla cost per infusion and per year
At Eli Lilly's list price of $731.49 per 350 mg/20 mL vial, a full 1,400 mg dose is $2,925.96, given once every 4 weeks. The first 13 infusions (52 weeks) come to $33,648.54 at list price.16
| Infusion | Dose | Vials | List price |
|---|---|---|---|
| Infusion 1 | 350 mg | 1 × 350 mg | $731.49 |
| Infusion 2 | 700 mg | 2 × 350 mg | $1,462.98 |
| Infusion 3 | 1,050 mg | 3 × 350 mg | $2,194.47 |
| Infusion 4 and later | 1,400 mg | 4 × 350 mg | $2,925.96 |
The label says to consider stopping when amyloid plaques fall to minimal levels on a PET scan, so the number of infusions differs from person to person.6
With Medicare Part B, the payment limit for a 1,400 mg dose (HCPCS J0175) is $2,929.50; 20% coinsurance on that is $585.90 per infusion, before the Part B deductible and without a Medigap or Medicare Advantage plan.2
List price read on the maker's page Oct 25, 2026. List price is what the maker charges wholesalers, not what you pay. These figures are for the medicine only: the clinic's infusion, MRI and PET charges are extra. Your doctor decides the dose and schedule.
Kisunla vs Leqembi: first-year list price
- Kisunla: $33,648.54, 13 infusions, one every 4 weeks.
- Leqembi: $24,984.70, 26 infusions, one every 2 weeks, for a 70 kg (154 lb) person.
Medicine only, at each maker's list price, on the label's starting schedule. A price comparison, not a comparison of how well they work.
With Medicare
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 20%.2 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
- CMS, National Coverage Determination 200.3 (anti-amyloid antibodies for Alzheimer's disease): "Effective April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of AD when furnished in accordance with Section B under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD."5
- Higher income? Part B and Part D premiums can include IRMAA: IRMAA brackets.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Eli Lilly: Kisunla pricing information. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (6)
“The list price of Kisunla is $731.49 per 350 mg/20 mL vial ... List price, also referred to as wholesale acquisition cost or WAC, is the price at which Lilly sells its products to wholesalers. ... WAC from AnalySource accessed on October 1, 2026.”
Eli Lilly: Kisunla pricing (entered by hand) · as of Oct 25, 2026- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026“Kisunla donanemab-azbt 7/2/2024 To treat Alzheimer’s disease”
FDA: Novel Drug Approvals for 2024 · as of Oct 25, 2026“Effective April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of AD when furnished in accordance with Section B under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.”
“Administer KISUNLA as an intravenous infusion over approximately 30 minutes every four weeks as follows ( 2.2 ): Infusion 1: 350 mg Infusion 2: 700 mg Infusion 3: 1,050 mg Infusion 4 and beyond: 1,400 mg Consider stopping dosing with KISUNLA based on reduction of amyloid plaques to minimal levels on amyloid PET imaging.”
FDA label (DailyMed): Kisunla, section 2 Dosage and Administration · as of Nov 6, 2026